Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease

Rheumatology (United Kingdom)

Volumn 54, Issue 12, 2015, Pages 2273-2282

  Tomcik, Michal ^a,b   Zerr, Pawel ^b   Palumbo Zerr, Katrin ^b   Storkanova, Hana ^a   Hulejova, Hana ^a   Spiritovic, Maja ^a   Kodet, Ondrej ^c   Stork, Jiri ^c   Becvar, Radim ^a   Vencovsky, Jiri ^a   Pavelka, Karel ^a   Filkova, Maria ^a   Distler, Jörg H W ^b   Senolt, Ladislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Capillaroscopy; Disease duration; Interleukin 35; Systemic sclerosis; TGF

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COLLAGEN; INTERLEUKIN 35; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CAPILLAROSCOPY; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; TURBIDIMETRY; UPREGULATION;

EID: 84983196972     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev260     Document Type: Article

References (46)

1. Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of disease: scleroderma. N Engl J Med 2009;360:1989-2003.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
3. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
4. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev 2008; 226:248-62
5. Collison LW, Delgoffe GM, Guy CS et al. The composition and signaling of the IL- 35 receptor are unconventional. Nat Immunol 2012;13:290-9.
6. Gu X, Tian T, Zhang B et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2015;36:2651-6.
7. Jin P, Ren H, Sun W et al. Circulating IL- 35 in pancreatic ductal adenocarcinoma patients. Hum Immunol 2014;75:29-33.
8. Liao KL, Bai XF, Friedman A. Mathematical modeling of interleukin- 35 promoting tumor growth and angiogenesis. PLoS ONE 2014;9:e110126.
9. Zeng JC, Zhang Z, Li TY et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Intern J Clin Exp Pathol 2013;6:1806-16.
10. Collison LW, Chaturvedi V, Henderson AL et al. IL-35- mediated induction of a potent regulatory T cell population. Nat Immunol 2010;11:1093-101.
11. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL- 35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
12. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL- 35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010;184:7144-53.
13. Niedbala W, Wei XQ, Cai B et al. IL- 35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th 17 cells. Eur J Immunol 2007;37:3021-9.
14. Wang RX, Yu CR, Dambuza IM et al. Interleukin- 35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014;20:633-41.
15. Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin- 35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol 2011;18:1125-32.
16. Thiolat A, Denys A, Petit M et al. Interleukin- 35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine 2014;69:87-93.
17. Ouyang H, Shi YB, Liu ZC et al. Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci 2014;348:156-61.
18. Ringkowski S, Thomas PS, Herbert C. Interleukin-12 family cytokines and sarcoidosis. Front Pharmacol 2014;5:233.
19. Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
20. Tomcik M, Palumbo-Zerr K, Zerr P et al. S100A 4 amplifies TGF-b-induced fibroblast activation in systemic sclerosis. Ann Rheum Dis 2014.
21. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
22. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
23. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
24. Becvar R, Stork J, Pesakova V et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005;1051:404-12.
25. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
26. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21(Suppl 29):S39-41.
27. Distler JH, Jungel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
28. Palumbo K, Zerr P, Tomcik M et al. The transcription factor JunD mediates transforming growth factor binduced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70:1320-6.
29. Dees C, Tomcik M, Palumbo-Zerr K et al. JAK- 2 as a novel mediator of the profibrotic effects of transforming growth factor b in systemic sclerosis. Arthritis Rheum 2012;64:3006-15.
30. Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010;6:578-87.
31. Trinchieri G, Pflanz S, Kastelein RA. The IL- 12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4.
32. Larousserie F, Bardel E, Coulomb L'Hermine A et al. Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas. J Pathol 2006;209:360-8.
33. Larousserie F, Pflanz S, Coulomb-L'Hermine A et al. Expression of IL- 27 in human Th1-associated granulomatous diseases. J Pathol 2004;202:164-71.
34. Niedobitek G, Päzolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)- induced gene, EBI3, an IL- 12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002;198:310-6.
35. Pflanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI 3 and p 28 protein, induces proliferation of naive CD4+ T cells. Immunity 2002;16:779-90.
36. Filkova M, Vernerova Z, Hulejova H et al. Pro-inflammatory effects of interleukin- 35 in rheumatoid arthritis. Cytokine 2015;73:36-43.
37. Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988;18:9-17.
38. Dieude P, Guedj M, Wipff J et al. STAT 4 is a genetic risk factor for systemic sclerosis having additive effects with IRF 5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009;60:2472-9.
39. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD 247 as a new susceptibility locus. Nat Genet 2010;42:426-9.
40. Avouac J, Furnrohr BG, Tomcik M et al. Inactivation of the transcription factor STAT- 4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011;63:800-9.
41. Bossini-Castillo L, Martin JE, Broen J et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 2012;21:926-33.
42. Rueda B, Broen J, Torres O et al. The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. Ann Rheum Dis 2009;68:253-6.
43. Yoshizaki A, Yanaba K, Iwata Y et al. Elevated serum interleukin- 27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis 2011;70:194-200.
44. Sato S, Hanakawa H, Hasegawa M et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000;27:2838-42.
45. Hamaguchi Y, Fujimoto M, Hasegawa M, Matsushita T, Takehara K. Bosentan increases serum IL- 12 levels in systemic sclerosis patients with pulmonary arterial hypertension. J Dermatol Sci 2009;55:66-7.
46. Komura K, Fujimoto M, Hasegawa M et al. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 2008;35:120-5.